文献速递创伤与烧伤复苏、休克与脓毒症

儿童创伤中血液制品的使用:来自TARN数据的经验教训

Blood product use in paediatric trauma: lessons from the TARN data.
PubMed 文献 · Emerg Med J · 2025-09-24
一句话结论英国创伤中心过去十年儿童创伤血液制品使用总体无显著变化,但年龄较大及穿透伤患儿使用增加,道路交通伤患儿使用减少。

该回顾性观察研究从英格兰、威尔士和北爱尔兰的创伤审计研究网络(TARN)提取2012至2021年10年数据,纳入16岁以下接受血液制品的受伤儿童。结果显示,2.5%(n=678)的受伤儿童在到院24小时内接受血液制品,包括院前环境;研究期间血液制品使用总体无显著变化(p=0.190)。10年间,年龄较大及穿透伤患儿血液制品使用显著增加(p<0.03),而道路交通伤相关儿童创伤的血液制品使用减少(p=0.01)。在接受血液制品的患儿中,60.5%在事发现场、25%在急诊科、12.8%在重症监护环境接受;最常见的是浓缩红细胞(84%),新鲜冰冻血浆、血小板和冷沉淀分别为9.7%、2.4%和1.6%。

要点

  • 研究期间2.5%(n=678)的受伤儿童在到院24小时内接受血液制品,包括院前环境。
  • 10年间儿童创伤血液制品使用总体无显著变化(p=0.190)。
  • 年龄较大及穿透伤患儿血液制品使用显著增加(p<0.03),道路交通伤患儿使用减少(p=0.01)。
  • 接受血液制品的患儿中,60.5%在事发现场、25%在急诊科、12.8%在重症监护环境接受。
  • 最常见血液制品为浓缩红细胞(84%),新鲜冰冻血浆9.7%、血小板2.4%、冷沉淀1.6%。

适用人群与场景

  • 纳入标准:英格兰、威尔士和北爱尔兰TARN站点中年龄小于16岁的受伤儿童或年轻人,接受血液制品(包括院前环境)。
  • 研究场景:院前、急诊科及重症监护环境。

研究设计与关键结果

  • 研究类型:回顾性观察研究,数据来自创伤审计研究网络(TARN),覆盖英格兰、威尔士和北爱尔兰站点,为期10年(2012-2021年)。
  • 样本量:2.5%(n=678)的受伤儿童在到院24小时内接受血液制品,包括院前环境。
  • 主要结果:研究期间血液制品使用总体无显著变化(p=0.190)。
  • 关键次要结果:10年间年龄较大及穿透伤患儿血液制品使用显著增加(p<0.03);道路交通伤相关儿童创伤的血液制品使用减少(p=0.01)。
  • 接受血液制品的地点分布:60.5%在事发现场,25%在急诊科,12.8%在重症监护环境。
  • 血液制品类型:浓缩红细胞84%,新鲜冰冻血浆9.7%,血小板2.4%,冷沉淀1.6%。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Trauma contributes significantly to childhood morbidity and mortality. Uncontrolled haemorrhage leading to cardiovascular collapse remains the leading cause of preventable death in paediatric trauma. Evidence to support the early and accurate identification of paediatric trauma patients requiring blood products is growing. Consensus guidelines advocating for more liberal blood product use based on the concept of damage control resuscitation and the introduction of risk predictor tools to identify children requiring resuscitation with blood products may have altered use in recent years. We aimed to identify trends in blood product prescribing practice in paediatric trauma resuscitation over the last decade.

METHODS: In this retrospective, observational study, data were abstracted from Trauma Audit Research Network (TARN) from sites in England, Wales and Northern Ireland over a 10-year period (2012-2021). Eligible cases were defined as injured children or young people aged less than 16 years who received blood products, including in the prehospital environment.

RESULTS: During the study period, 2.5% (n=678) of injured children received blood products within 24 hours of hospital arrival, including the prehospital environment. Blood product administration over the study period remained largely unchanged (p=0.190). Over the 10-year period, we saw a significant increase in blood product use among paediatric trauma patients of increasing age and those with penetrating injuries (p<0.03). By contrast, there was a decrease in blood product use across the same 10-year period among paediatric trauma related to road traffic collisions (p=0.01). On analysing the paediatric trauma population that received blood products, the distribution across locations can be seen as follows: 60.5% received blood products at the scene of the incident, 25% in the ED and 12.8% in critical care settings. The most common blood product given was packed red blood cells (84%), with fresh frozen plasma, platelets and cryoprecipitate administered in 9.7%, 2.4% and 1.6% of cases, respectively.

CONCLUSION: UK trauma centres have not significantly changed blood product use in paediatric trauma over the last decade. Monitoring and understanding national blood product use in paediatric trauma is integral to understanding trends and current practice.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Mullan K, McAlister P, Mc Veigh SM, et al. Blood product use in paediatric trauma: lessons from the TARN data. Emerg Med J. 2025. PMID: 40210465. doi:10.1136/emermed-2024-214397

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。